Reboxitin for ADHD
Reboxitin is a norepinephrine reuptake inhibitor, alongside weak serotonin reuptake inhibition.
Trade names: Edronax (D, CH, A), Solcenx (D)
Reboxitin is a noradrenergic drug that has been reported to be effective in ADHD. As an antidepressant, as it was actually intended, it was probably quite unsuccessful.
The updated European Consensus on the Diagnosis and Treatment of ADHD (2018) names reboxitine as a possible alternative to atomoxetine for ADHD.1
There is evidence of efficacy of reboxitin in ADHD. However, there are only a few controlled studies.Reboxitin could be used primarily in adults without comorbidities.23
In Germany, Reboxitin is not reimbursed by health insurance companies.
Kooij, Bijlenga, Salerno, Jaeschke, Bitter, Balázs, Thome, Dom, Kasper, Filipe, Stes, Mohr, Leppämäki, Brugué, Bobes, Mccarthy, Richarte, Philipsen, Pehlivanidis, Niemela, Styr, Semerci, Bolea-Alamanac, Edvinsson, Baeyens, Wynchank, Sobanski, Philipsen, McNicholas, Caci, Mihailescu, Manor, Dobrescu, Krause, Fayyad, Ramos-Quiroga, Foeken, Rad, Adamou, Ohlmeier, Fitzgerald, Gill, Lensing, Mukaddes, Brudkiewicz, Gustafsson, Tania, Oswald, Carpentier, De Rossi, Delorme, Simoska, Pallanti, Young, Bejerot, Lehtonen, Kustow, Müller-Sedgwick, Hirvikoski, Pironti, Ginsberg, Félegeházy, Garcia-Portilla, Asherson (2018): Updated European Consensus Statement on diagnosis and treatment of adult ADHD, European Psychiatrie, European Psychiatry 56 (2019) 14–34, http://dx.doi.org/10.1016/j.eurpsy.2018.11.001, Seite 23, 7.4.7. ↥
Ghanizadeh (2015): A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder. Nord J Psychiatry. 2015 May;69(4):241-8. doi: 10.3109/08039488.2014.972975. PMID: 25415763. REVIEW ↥
Riahi, Tehrani-Doost, Shahrivar, Alaghband-Rad (2010): Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial. Hum Psychopharmacol. 2010 Nov;25(7-8):570-6. doi: 10.1002/hup.1158. ↥